Hoyuan Biotech (688238.SH): Shareholders Shanghai Tan Ying, Shanghai Qiangang, and Shanghai Leyong have collectively reduced their shareholding by 0.9990% in the company.
On September 9th, Gelonghui announced that Hemay Bio (688238.SH) has recently received a notice from shareholders Shanghai Tianying, Shanghai Qiangang, and Shanghai Leyong regarding the expiration of the shareholding reduction plan and equity changes reaching 1%. As of September 6th, 2024, shareholders Shanghai Tianying, Shanghai Qiangang, and Shanghai Leyong have cumulatively reduced the company's shareholding through centralized bidding trading by 6,467,856 shares, holding a total of 45,871,444 shares. The shareholding reduction plan of shareholders Shanghai Tianying, Shanghai Qiangang, and Shanghai Leyong has reached the end of the designated time range, and this shareholding reduction plan has been fully implemented.
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
HiFiBio (688238.SH) released its semi-annual performance results with a net loss of 113 million yuan.
Huayuan Biology (688238.SH) disclosed its semi-annual report for 2024, and the company achieved revenue of 1.13 million during the reporting period...
Hua Yuan Bio (688238.SH): net loss of 0.113 billion yuan in the first half of the year.
Gelonghui released its semi-annual report on August 28. During the reporting period, the company achieved operating revenue of 113.0616 million yuan, a year-on-year increase of 35.00%. The net income attributable to the owners of the parent company was -113.3454 million yuan, and the net income attributable to the owners of the parent company after deducting non-recurring gains and losses was -119.4092 million yuan, a decrease compared to the same period last year. The net cash flow from operating activities was -114.6298 million yuan, a decrease compared to the same period last year. This is mainly due to the continuous impact of the external investment and financing environment, as well as the domestic cell and foundation.
OBiO Technology Congratulates on The First Clinical Gene Editing Therapy to Treat An Overseas Patient in China by CorrectSequence Therapeutics
Revolutionizing Stroke Treatment: The Ottawa Hospital First To Adopt Vena Medical's Innovative Device
The Healthcare Businesswomen's Association Announces Inaugural Pitch Competition for Women Innovators With Cash Prizes Up to $100K
2023 Annual Report (updated version)
OBiO Technology Officially Launched the Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases
Heyuan Biotech (688238.SH): The first phase of the employee stock ownership plan completed the stock purchase
Gelonghui, May 30丨Heyuan Biotech (688238.SH) announced that as of May 30, 2024, the first phase of the employee stock ownership plan had completed the purchase of the company's shares. A total of 5,508,413 shares were purchased through secondary market purchases, accounting for 0.8508% of the company's current total share capital. The average transaction price was 5.6261 yuan/share, and the total transaction amount was 30,990,802.88 yuan. The above shares will be locked in accordance with the relevant regulations of this employee stock ownership plan. The lockdown period is 12 months, that is, from May 31, 2024 to May 30, 2025
Obio Technology's Shareholders to Offload Up to 1.5% Stake
Heyuan Biology (688238.SH): Focuses on providing CRO services such as gene therapy vector development and gene function research for basic cell gene therapy research
Gelonghui, May 14, and Heyuan Biology (688238.SH) said on an interactive platform that synthetic biology enables biological production of various products by designing and constructing new biological components (such as enzymes, gene expression systems, etc.) and biological systems (such as microbial production systems, cell factories, etc.). These products include medicinal or preventive biological products such as proteins, antibodies, and viruses, biofuels, environmentally friendly materials, food, or providing new treatments for medicine. Therefore, broadly speaking, the development and large-scale production of gene and cell therapies are closely related to the development of synthetic biology technology. The company is deeply involved in cell gene therapy
OBiO Technology Will Showcase at American Society of Gene & Cell Therapy
Heyuan Biotech (688238.SH) announced its 2023 annual results, with a net loss of 128 million yuan, changing from profit to loss over the previous year
Heyuan Biotech (688238.SH) disclosed its 2023 annual report, and the company achieved revenue of 2 in 2023...
Obio Technology (Shanghai) Corp., Ltd. (SHSE:688238) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Is Obio Technology (Shanghai) (SHSE:688238) Using Too Much Debt?
5.2 million restricted shares of Heyuan Biotech (688238.SH) will be listed and circulated on March 22
Heyuan Biotech (688238.SH) announced that the total number of shares in circulation in the company's current stock listing is 5.2 million shares, which are listed and in circulation...
Heyuan Biotech (688238.SH) Performance Report: Net loss of 128 million yuan in 2023
On February 23, Gelonghui (688238.SH) announced its 2023 annual performance report. During the reporting period, the company achieved operating income of 213.0462 million yuan, a decrease of 26.86% over the same period of the previous year; realized net profit attributable to owners of the parent company - 12,8013,500 yuan, a decrease of 16.727 million yuan over the same period of the previous year; realized net profit attributable to owners of the parent company after deduction of non-recurring profit and loss - 13.32417 million yuan, a decrease of 164.2681 million yuan from the same period last year.
Heyuan Biotech (688238.SH): The first phase of the employee stock ownership plan will raise no more than 50 million yuan
On February 7, Gelonghui (688238.SH) announced the first phase of the employee stock ownership plan. The total amount of self-financing funds raised by employees in the employee stock ownership plan was no more than 30 million yuan, which was a ratio of 6:4 with the incentive fund withdrawn by the company. The amount of incentive funds withdrawn by the company according to the “Remuneration Management System” did not exceed RMB 20 million. The total amount of capital to be raised in this employee stock ownership plan is not more than RMB 50 million. Using “shares” as the subscription unit, each share is 1 yuan, and the total subscription share is no more than 50 million shares. The specific share is determined based on the actual amount of funding contributions.
No Data
No Data